Gilead to Acquire Tubulis to Expand ADC Oncology Platform

Gilead Sciences has announced an acquisition of Tubulis to strengthen its oncology pipeline with an antibody-drug conjugate (ADC) and an expanded platform. The deal adds TUB-040, a NaPi2b-targeting ADC candidate for ovarian cancer and other solid tumors.

Gilead also described Tubulis as bringing an industry-leading ADC platform that includes its clinically validated Tubutecan linker-payload technology, along with a next-generation platform intended to expand Gilead’s ADC capabilities.